Narcolepsy Drugs Market by Disease Type (Daytime Extreme Sleepiness, Cataplexia, and Others) and Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026
Narcolepsy is characterized by several symptoms that include cataplexy, excessive daytime sleepiness, hallucinations, and sleep paralysis. In addition, patients suffering from narcolepsy experience automatic behaviors such as eating, walking, or driving, in a dazed manner. Symptoms differ from patient to patient, and are diagnosed between the ages of 7 and 25. The global narcolepsy drugs market accounted for around $2,429 million in 2018, and is expected to reach $5,360 million by 2026, registering a CAGR of 10.3% from 2019 to 2026.
Although narcolepsy is a rare and underdiagnosed chronic condition, many cases have been reported of the people affected by this disease. It was estimated that more than 1 in 2,000 people in the U.S. were affected by narcolepsy in 2012. Increase in severity of the disease and rise in the number of people being affected by narcolepsy are some of the key driving factors of the market. Furthermore, the availability of reimbursement for FDA-approved prescription medicines is expected to fuel the demand for these drugs. However, lack of awareness regarding the diagnosis and treatment availability hinders the market growth. Conversely, increase in the number of programs by various organizations to spread awareness regarding the importance of early narcolepsy diagnosis is anticipated to offer lucrative opportunities for market expansion.
The global narcolepsy drugs market is segmented based on disease type, therapeutics type, and geography. Depending on disease type, the market is categorized into daytime extreme sleepiness, cataplexia, and others. By therapeutics type, it is segregated into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and others. Region wise, the market is examined across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc., Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc., Bioprojet, and Graymark Healthcare, Inc. have been provided in this report. Product launch and technological advancements are the few strategies adopted by the key players of the global narcolepsy drugs market.
KEY BENEFITS FOR STAKEHOLDERS
Although narcolepsy is a rare and underdiagnosed chronic condition, many cases have been reported of the people affected by this disease. It was estimated that more than 1 in 2,000 people in the U.S. were affected by narcolepsy in 2012. Increase in severity of the disease and rise in the number of people being affected by narcolepsy are some of the key driving factors of the market. Furthermore, the availability of reimbursement for FDA-approved prescription medicines is expected to fuel the demand for these drugs. However, lack of awareness regarding the diagnosis and treatment availability hinders the market growth. Conversely, increase in the number of programs by various organizations to spread awareness regarding the importance of early narcolepsy diagnosis is anticipated to offer lucrative opportunities for market expansion.
The global narcolepsy drugs market is segmented based on disease type, therapeutics type, and geography. Depending on disease type, the market is categorized into daytime extreme sleepiness, cataplexia, and others. By therapeutics type, it is segregated into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and others. Region wise, the market is examined across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc., Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc., Bioprojet, and Graymark Healthcare, Inc. have been provided in this report. Product launch and technological advancements are the few strategies adopted by the key players of the global narcolepsy drugs market.
KEY BENEFITS FOR STAKEHOLDERS
- This report highlights the market dynamics to understand the global narcolepsy drugs market and capitalize on the prevailing opportunities.
- Quantitative analysis of the current market and forecasts assists stakeholders to design business strategies accordingly.
- Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
- Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.
- By Disease Type
- Daytime Extreme Sleepiness
- Cataplexia
- Others
- By Therapeutics Type
- Central Nervous System Stimulants
- Tricyclic Antidepressants
- Sodium Oxybate
- Selective Serotonin Reuptake Inhibitor
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- Spain
- Italy
- UK
- Rest of Europe
- Asia-Pacific
- Australia
- Japan
- India
- China
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Ligand Pharmaceuticals
- Addrenex Pharmaceuticals
- Shire Plc.
- Teva Pharmaceutical Industries Ltd.
- Arena Pharmaceuticals
- Jazz Pharmaceuticals Plc.
- Bioprojet
- Graymark Healthcare, Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Parent Market Overview
3.3. Key Forces Shaping Narcolepsy Drugs Market
3.3.1. Moderate bargaining power of suppliers
3.3.2. Low bargaining power of buyers
3.3.3. Low threat of new entrants
3.3.4. Moderate threat of substitutes
3.3.5. Moderate intensity of rivalry
3.4. Pricing Analysis
3.4.1. Pricing Analysis, By Region, 2018 & 2025
3.5. Market Evolution
3.6. Value Chain Analysis
3.7. Impact of government regulations on global narcolepsy drugs market
3.8. Patent Analysis
3.8.1. By Region
3.8.2. By Applicant
3.9. Market Dynamics
3.9.1. Drivers
3.9.1.1. Increase in global prevalence of narcolepsy
3.9.1.2. Narcolepsy awareness programs and services
3.9.1.3. Presence of reimbursement policies regarding narcolepsy
3.9.2. Restraints
3.9.2.1. Adverse effects and risks related to narcolepsy drugs
3.9.2.2. Delayed diagnosis or misdiagnosis
3.9.3. Opportunity
3.9.3.1. Untapped markets in the developing countries
CHAPTER 4: NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Daytime Extreme Sleepiness
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Cataplexia
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Other Disease Type
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Central Nervous System Stimulants
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Tricyclic Antidepressants
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Sodium Oxybate
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Selective Serotonin Reuptake Inhibitor
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Other Therapeutic Type
5.6.1. Market size and forecast
5.6.2. Market analysis, by country
CHAPTER 6: NARCOLEPSY DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America market size and forecast, by disease type
6.2.3. North America market size and forecast, by therapeutic type
6.2.4. North America market size and forecast, by country
6.2.4.1. U.S. market size and forecast, by disease type
6.2.4.2. U.S. market size and forecast, by therapeutic type
6.2.4.3. Canada market size and forecast, by disease type
6.2.4.4. Canada market size and forecast, by therapeutic type
6.2.4.5. Mexico market size and forecast, by disease type
6.2.4.6. Mexico market size and forecast, by therapeutic type
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe market size and forecast, by disease type
6.3.3. Europe market size and forecast, by therapeutic type
6.3.4. Europe market size and forecast, by country
6.3.4.1. Germany market size and forecast, by disease type
6.3.4.2. Germany market size and forecast, by therapeutic type
6.3.4.3. France market size and forecast, by disease type
6.3.4.4. France market size and forecast, by therapeutic type
6.3.4.5. UK market size and forecast, by disease type
6.3.4.6. UK market size and forecast, by therapeutic type
6.3.4.7. Italy market size and forecast, by disease type
6.3.4.8. Italy market size and forecast, by therapeutic type
6.3.4.9. Spain market size and forecast, by disease type
6.3.4.10. Spain market size and forecast, by therapeutic type
6.3.4.11. Rest of Europe market size and forecast, by disease type
6.3.4.12. Rest of Europe market size and forecast, by therapeutic type
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific market size and forecast, by disease type
6.4.3. Asia-Pacific market size and forecast, by therapeutic type
6.4.4. Asia-Pacific market size and forecast, by country
6.4.4.1. Japan market size and forecast, by disease type
6.4.4.2. Japan market size and forecast, by therapeutic type
6.4.4.3. China market size and forecast, by disease type
6.4.4.4. China market size and forecast, by therapeutic type
6.4.4.5. Australia market size and forecast, by disease type
6.4.4.6. Australia market size and forecast, by therapeutic type
6.4.4.7. India market size and forecast, by disease type
6.4.4.8. India market size and forecast, by therapeutic type
6.4.4.9. South Korea market size and forecast, by disease type
6.4.4.10. South Korea market size and forecast, by therapeutic type
6.4.4.11. Rest of Asia-Pacific market size and forecast, by disease type
6.4.4.12. Rest of Asia-Pacific market size and forecast, by therapeutic type
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA market size and forecast, by disease type
6.5.3. LAMEA market size and forecast, by therapeutic type
6.5.4. LAMEA market size and forecast, by country
6.5.4.1. Brazil market size and forecast, by disease type
6.5.4.2. Brazil market size and forecast, by therapeutic type
6.5.4.3. Saudi market size and forecast, by disease type
6.5.4.4. Saudi market size and forecast, by therapeutic type
6.5.4.5. South Africa market size and forecast, by disease type
6.5.4.6. South Africa market size and forecast, by therapeutic type
6.5.4.7. Rest of LAMEA market size and forecast, by disease type
6.5.4.8. Rest of LAMEA market size and forecast, by therapeutic type
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Market Share Analysis of Top Players, 2018 (%)
7.3. Product Mapping of Top Players
7.4. Competitive Heatmap
CHAPTER 8: COMPANY PROFILES
8.1. ARENA PHARMACEUTICAL, INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.2. BIOPROJET PHARMA SARL
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.3. JAZZ PHARMACEUTICAL PLC
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Operating segments
8.3.5. Business Performance
8.3.6. Key strategic moves and developments
8.4. LIGAND PHARMACEUTICALS INCORPORATED
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.5. NOVARTIS INTERNATIONAL AG
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. SHINOGI INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. TAKEDA PHARMACEUTICAL COMPANY
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Parent Market Overview
3.3. Key Forces Shaping Narcolepsy Drugs Market
3.3.1. Moderate bargaining power of suppliers
3.3.2. Low bargaining power of buyers
3.3.3. Low threat of new entrants
3.3.4. Moderate threat of substitutes
3.3.5. Moderate intensity of rivalry
3.4. Pricing Analysis
3.4.1. Pricing Analysis, By Region, 2018 & 2025
3.5. Market Evolution
3.6. Value Chain Analysis
3.7. Impact of government regulations on global narcolepsy drugs market
3.8. Patent Analysis
3.8.1. By Region
3.8.2. By Applicant
3.9. Market Dynamics
3.9.1. Drivers
3.9.1.1. Increase in global prevalence of narcolepsy
3.9.1.2. Narcolepsy awareness programs and services
3.9.1.3. Presence of reimbursement policies regarding narcolepsy
3.9.2. Restraints
3.9.2.1. Adverse effects and risks related to narcolepsy drugs
3.9.2.2. Delayed diagnosis or misdiagnosis
3.9.3. Opportunity
3.9.3.1. Untapped markets in the developing countries
CHAPTER 4: NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Daytime Extreme Sleepiness
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Cataplexia
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Other Disease Type
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Central Nervous System Stimulants
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Tricyclic Antidepressants
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Sodium Oxybate
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Selective Serotonin Reuptake Inhibitor
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Other Therapeutic Type
5.6.1. Market size and forecast
5.6.2. Market analysis, by country
CHAPTER 6: NARCOLEPSY DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America market size and forecast, by disease type
6.2.3. North America market size and forecast, by therapeutic type
6.2.4. North America market size and forecast, by country
6.2.4.1. U.S. market size and forecast, by disease type
6.2.4.2. U.S. market size and forecast, by therapeutic type
6.2.4.3. Canada market size and forecast, by disease type
6.2.4.4. Canada market size and forecast, by therapeutic type
6.2.4.5. Mexico market size and forecast, by disease type
6.2.4.6. Mexico market size and forecast, by therapeutic type
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe market size and forecast, by disease type
6.3.3. Europe market size and forecast, by therapeutic type
6.3.4. Europe market size and forecast, by country
6.3.4.1. Germany market size and forecast, by disease type
6.3.4.2. Germany market size and forecast, by therapeutic type
6.3.4.3. France market size and forecast, by disease type
6.3.4.4. France market size and forecast, by therapeutic type
6.3.4.5. UK market size and forecast, by disease type
6.3.4.6. UK market size and forecast, by therapeutic type
6.3.4.7. Italy market size and forecast, by disease type
6.3.4.8. Italy market size and forecast, by therapeutic type
6.3.4.9. Spain market size and forecast, by disease type
6.3.4.10. Spain market size and forecast, by therapeutic type
6.3.4.11. Rest of Europe market size and forecast, by disease type
6.3.4.12. Rest of Europe market size and forecast, by therapeutic type
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific market size and forecast, by disease type
6.4.3. Asia-Pacific market size and forecast, by therapeutic type
6.4.4. Asia-Pacific market size and forecast, by country
6.4.4.1. Japan market size and forecast, by disease type
6.4.4.2. Japan market size and forecast, by therapeutic type
6.4.4.3. China market size and forecast, by disease type
6.4.4.4. China market size and forecast, by therapeutic type
6.4.4.5. Australia market size and forecast, by disease type
6.4.4.6. Australia market size and forecast, by therapeutic type
6.4.4.7. India market size and forecast, by disease type
6.4.4.8. India market size and forecast, by therapeutic type
6.4.4.9. South Korea market size and forecast, by disease type
6.4.4.10. South Korea market size and forecast, by therapeutic type
6.4.4.11. Rest of Asia-Pacific market size and forecast, by disease type
6.4.4.12. Rest of Asia-Pacific market size and forecast, by therapeutic type
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA market size and forecast, by disease type
6.5.3. LAMEA market size and forecast, by therapeutic type
6.5.4. LAMEA market size and forecast, by country
6.5.4.1. Brazil market size and forecast, by disease type
6.5.4.2. Brazil market size and forecast, by therapeutic type
6.5.4.3. Saudi market size and forecast, by disease type
6.5.4.4. Saudi market size and forecast, by therapeutic type
6.5.4.5. South Africa market size and forecast, by disease type
6.5.4.6. South Africa market size and forecast, by therapeutic type
6.5.4.7. Rest of LAMEA market size and forecast, by disease type
6.5.4.8. Rest of LAMEA market size and forecast, by therapeutic type
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Market Share Analysis of Top Players, 2018 (%)
7.3. Product Mapping of Top Players
7.4. Competitive Heatmap
CHAPTER 8: COMPANY PROFILES
8.1. ARENA PHARMACEUTICAL, INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.2. BIOPROJET PHARMA SARL
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.3. JAZZ PHARMACEUTICAL PLC
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Operating segments
8.3.5. Business Performance
8.3.6. Key strategic moves and developments
8.4. LIGAND PHARMACEUTICALS INCORPORATED
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.5. NOVARTIS INTERNATIONAL AG
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. SHINOGI INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. TAKEDA PHARMACEUTICAL COMPANY
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
LIST OF TABLES
TABLE 01. GLOBAL NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026 ($MILLION)
TABLE 02. NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY REGION, 2018–2026 ($MILLION)
TABLE 03. NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY REGION, 2018–2026 ($MILLION)
TABLE 04. NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY REGION, 2018–2026 ($MILLION)
TABLE 05. GLOBAL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 06. NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY REGION, 2018–2026, ($MILLION)
TABLE 07. NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018–2026, ($MILLION)
TABLE 08. NARCOLEPSY DRUGS MARKET FOR SODIUM OXYBATE, BY REGION, 2018–2026, ($MILLION)
TABLE 09. NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY REGION, 2018–2026, ($MILLION)
TABLE 10. NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY REGION, 2018–2026, ($MILLION)
TABLE 11. NARCOLEPSY DRUGS MARKET, BY REGION, 2018–2026, ($MILLION)
TABLE 12. NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 13. NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 14. NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 15. U.S. NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 16. U.S. NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 17. CANADA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 18. CANADA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 19. MEXICO NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 20. MEXICO NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 21. EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 22. EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 23. EUROPE NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 24. GERMANY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 25. GERMANY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 26. FRANCE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 27. FRANCE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 28. UK NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 29. UK NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 30. ITALY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 31. ITALY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 32. SPAIN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 33. SPAIN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 34. REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 35. REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 36. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 37. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 38. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 39. JAPAN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 40. JAPAN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 41. CHINA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 42. CHINA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 43. AUSTRALIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 44. AUSTRALIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 45. INDIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 46. INDIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 47. SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 48. SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 50. REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 51. LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 52. LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 53. LAMEA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 54. BRAZIL NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 55. BRAZIL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 56. SAUDI NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 57. SAUDI NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 58. SOUTH AFRICA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 59. SOUTH AFRICA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 60. REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 61. REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 62. ARENA: COMPANY SNAPSHOT
TABLE 63. ARENA: OPERATING SEGMENTS
TABLE 64. BIOPROJET PHARMA: COMPANY SNAPSHOT
TABLE 65. BIOPROJET: OPERATING BUSINESS SEGMENTS
TABLE 66. JAZZ: COMPANY SNAPSHOT
TABLE 67. JAZZ: OPERATING SEGMENTS
TABLE 68. JAZZ: OPERATING SEGMENTS
TABLE 69. LIGAND PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 70. LIGAND PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 71. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 72. NOVARTIS: OPERATING SEGMENTS
TABLE 73. SHIONOGI: COMPANY SNAPSHOT
TABLE 74. SHIONOGI: OPERATING SEGMENTS
TABLE 75. SHIONOGI: PRODUCT PORTFOLIO
TABLE 76. TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 77. TAKEDA PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 78. TEVA: COMPANY SNAPSHOT
TABLE 79. TEVA: OPERATING SEGMENTS
TABLE 80. TEVA: PRODUCT PORTFOLIO
TABLE 01. GLOBAL NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026 ($MILLION)
TABLE 02. NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY REGION, 2018–2026 ($MILLION)
TABLE 03. NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY REGION, 2018–2026 ($MILLION)
TABLE 04. NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY REGION, 2018–2026 ($MILLION)
TABLE 05. GLOBAL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 06. NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY REGION, 2018–2026, ($MILLION)
TABLE 07. NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018–2026, ($MILLION)
TABLE 08. NARCOLEPSY DRUGS MARKET FOR SODIUM OXYBATE, BY REGION, 2018–2026, ($MILLION)
TABLE 09. NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY REGION, 2018–2026, ($MILLION)
TABLE 10. NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY REGION, 2018–2026, ($MILLION)
TABLE 11. NARCOLEPSY DRUGS MARKET, BY REGION, 2018–2026, ($MILLION)
TABLE 12. NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 13. NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 14. NORTH AMERICA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 15. U.S. NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 16. U.S. NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 17. CANADA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 18. CANADA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 19. MEXICO NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 20. MEXICO NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 21. EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 22. EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 23. EUROPE NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 24. GERMANY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 25. GERMANY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 26. FRANCE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 27. FRANCE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 28. UK NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 29. UK NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 30. ITALY NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 31. ITALY NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 32. SPAIN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 33. SPAIN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 34. REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 35. REST OF EUROPE NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 36. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 37. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 38. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 39. JAPAN NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 40. JAPAN NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 41. CHINA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 42. CHINA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 43. AUSTRALIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 44. AUSTRALIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 45. INDIA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 46. INDIA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 47. SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 48. SOUTH KOREA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 50. REST OF ASIA-PACIFIC NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 51. LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 52. LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 53. LAMEA NARCOLEPSY DRUGS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 54. BRAZIL NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 55. BRAZIL NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 56. SAUDI NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 57. SAUDI NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 58. SOUTH AFRICA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 59. SOUTH AFRICA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 60. REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE, 2018–2026, ($MILLION)
TABLE 61. REST OF LAMEA NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE, 2018–2026, ($MILLION)
TABLE 62. ARENA: COMPANY SNAPSHOT
TABLE 63. ARENA: OPERATING SEGMENTS
TABLE 64. BIOPROJET PHARMA: COMPANY SNAPSHOT
TABLE 65. BIOPROJET: OPERATING BUSINESS SEGMENTS
TABLE 66. JAZZ: COMPANY SNAPSHOT
TABLE 67. JAZZ: OPERATING SEGMENTS
TABLE 68. JAZZ: OPERATING SEGMENTS
TABLE 69. LIGAND PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 70. LIGAND PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 71. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 72. NOVARTIS: OPERATING SEGMENTS
TABLE 73. SHIONOGI: COMPANY SNAPSHOT
TABLE 74. SHIONOGI: OPERATING SEGMENTS
TABLE 75. SHIONOGI: PRODUCT PORTFOLIO
TABLE 76. TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 77. TAKEDA PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 78. TEVA: COMPANY SNAPSHOT
TABLE 79. TEVA: OPERATING SEGMENTS
TABLE 80. TEVA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. PARENT MARKET
FIGURE 02. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 03. LOW BARGAINING POWER OF BUYERS
FIGURE 04. LOW THREAT OF NEW ENTRANTS
FIGURE 05. MODERATE THREAT OF SUBSTITUTES
FIGURE 06. MODERATE INTENSITY OF RIVALRY
FIGURE 07. PRICING ANALYSIS, BY REGION, 2018 & 2025
FIGURE 08. VALUE CHAIN ANALYSIS
FIGURE 09. PATENT ANALYSIS, BY REGION, (2014-2018)
FIGURE 10. PATENT ANALYSIS, BY APPLICANT, (2014-2018)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR SODIUM OXYBATE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. MARKET SHARE ANALYSIS: NARCOLEPSY DRUGS MARKET, 2018 (%)
FIGURE 20. PRODUCT MAPPING OF TOP PLAYERS
FIGURE 21. COMPETITIVE HEATMAP
FIGURE 22. ARENA: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. JAZZ: NET SALES, 2016-2018 ($MILLION)
FIGURE 24. JAZZ: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 25. LIGAND PHARMACEUTICAL: NET SALES, 2016–2018 ($MILLION)
FIGURE 26. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 27. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 29. SHIONOGI: NET SALES, 2016–2018 ($MILLION)
FIGURE 30. SHIONOGI: BY REGION, 2018 (%)
FIGURE 31. TAKEDA: NET SALES, 2016–2018 ($MILLION)
FIGURE 32. TAKEDA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 33. TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 34. TEVA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 01. PARENT MARKET
FIGURE 02. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 03. LOW BARGAINING POWER OF BUYERS
FIGURE 04. LOW THREAT OF NEW ENTRANTS
FIGURE 05. MODERATE THREAT OF SUBSTITUTES
FIGURE 06. MODERATE INTENSITY OF RIVALRY
FIGURE 07. PRICING ANALYSIS, BY REGION, 2018 & 2025
FIGURE 08. VALUE CHAIN ANALYSIS
FIGURE 09. PATENT ANALYSIS, BY REGION, (2014-2018)
FIGURE 10. PATENT ANALYSIS, BY APPLICANT, (2014-2018)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR DAYTIME EXTREME SLEEPINESS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR CATAPLEXIA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR OTHER DISEASE TYPE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM STIMULANTS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR SODIUM OXYBATE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF NARCOLEPSY DRUGS MARKET FOR OTHER THERAPEUTIC TYPE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. MARKET SHARE ANALYSIS: NARCOLEPSY DRUGS MARKET, 2018 (%)
FIGURE 20. PRODUCT MAPPING OF TOP PLAYERS
FIGURE 21. COMPETITIVE HEATMAP
FIGURE 22. ARENA: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. JAZZ: NET SALES, 2016-2018 ($MILLION)
FIGURE 24. JAZZ: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 25. LIGAND PHARMACEUTICAL: NET SALES, 2016–2018 ($MILLION)
FIGURE 26. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 27. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 29. SHIONOGI: NET SALES, 2016–2018 ($MILLION)
FIGURE 30. SHIONOGI: BY REGION, 2018 (%)
FIGURE 31. TAKEDA: NET SALES, 2016–2018 ($MILLION)
FIGURE 32. TAKEDA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 33. TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 34. TEVA: REVENUE SHARE BY REGION, 2018 (%)
